Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 26

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
 acting as the placement agent
for the January 2025 Offering, in addition to certain cash fees, the Company issued H.C. Wainwright & Co., LLC (the “Placement
Agent”) warrants to purchase up to 15,325 shares of common stock at an exercise price of $6.382 (the “January 2025 Agent Warrants”).
The January 2025 Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.

February 2025 Offering

On February 5, 2025, the Company entered into
a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering
priced at-the-market under the rules of Nasdaq, an aggregate of 300,700 shares of the Company’s common stock at a purchase price
of $3.575 per share. In a concurrent private placement, the Company separately issued to the investors unregistered warrants to purchase
up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share (the “February 2025 Warrants”).
The February 2025 Warrants were immediately exercisable upon issuance and expire twenty-four months from the date of issuance. The registered
direct offering and concurrent private placement (together, the “February 2025 Offering”) closed on February 6, 2025, resulting
in net proceeds to the Company of approximately $908,627, after deducting the placement agent fees and other offering expenses paid by
the Company.

As compensation for acting as the placement agent
for the February 2025 Offering, in addition to certain cash fees, the Company issued the Placement Agent warrants to purchase up to 22,554
shares of common stock at an exercise price of $4.469 (the “February 2025 Agent Warrants”). The February 2025 Agent Warrants
were exercisable upon issuance and expire twenty-four months from the date of issuance.

January 2024 Offering

On January 29, 2024, the Company closed its public
offering (the “January 2024 Offering”) consisting of (i) 87,682 units consisting of one share of common stock and one warrant
exercisable for one share of common stock (the “January 2024 Warrants”), and (ii) 16,652 pre-funded units consisting of one
pre-funded warrant exercisable for one share of common stock (the “January